IMRX · Immuneering Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | $0 | $317.0K | $2.31M |
| Cost of Revenue | - | - | $0 | $158.1K | $1.28M |
| Gross Profit | - | - | $0 | $158.8K | $1.03M |
| R&D | $42.05M | $47.96M | $41.62M | $36.27M | $15.00M |
| SG&A | $17.30M | $16.08M | $16.76M | $15.61M | $3.11M |
| Total Operating Expenses | $59.38M | $64.07M | $58.41M | $51.90M | $18.11M |
| D&A | $324.5K | $355.8K | $322.8K | $247.2K | $24.3K |
| Operating Income | ($59.38M) | ($64.07M) | ($58.41M) | ($51.74M) | ($17.08M) |
| Interest Expense | - | - | - | - | - |
| Income Tax | $0 | - | - | - | ($307.5K) |
| Net Income | ($56.02M) | ($61.04M) | ($53.47M) | ($50.51M) | ($17.04M) |
| EPS - Basic | ($1.27) | ($2.04) | ($1.88) | ($1.91) | ($3.44) |
| EPS - Diluted | ($1.27) | ($2.04) | ($1.88) | ($1.90) | ($3.44) |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $128.65M | $36.14M | $59.41M | $72.64M | $74.89M |
| Accounts Receivable | - | - | $0 | $12.4K | $246.0K |
| Inventory | - | - | - | - | - |
| Accounts Payable | $1.54M | $1.96M | $2.11M | $3.15M | $1.39M |
| Current Assets | $176.25M | $39.59M | $89.08M | $108.75M | $152.33M |
| Total Assets | $231.99M | $52.71M | $102.58M | $122.37M | $166.70M |
| Current Liabilities | $10.07M | $7.50M | $7.85M | $8.05M | $5.63M |
| Long-term Debt | - | - | - | - | - |
| Total Liabilities | $13.50M | $11.33M | $12.01M | $12.52M | $10.72M |
| Stockholders' Equity | $218.48M | $41.39M | $90.58M | $109.85M | $155.98M |
| Retained Earnings | ($280.32M) | ($224.30M) | ($163.26M) | ($109.79M) | ($59.27M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($45.34M) | ($55.00M) | ($48.97M) | ($44.10M) | ($14.62M) |
| Investing Cash Flow | ($88.74M) | $26.43M | $7.30M | $41.83M | ($53.4K) |
| Financing Cash Flow | $226.58M | $5.30M | $28.44M | $19.0K | $37.98M |
| CapEx | $142.2K | $84.9K | $342.7K | $742.5K | $53.4K |
| Free Cash Flow | ($45.49M) | ($55.08M) | ($49.31M) | ($44.84M) | ($14.67M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | - | - | - | 50.1% | 44.6% |
| Operating margin | - | - | - | -16325.8% | -739.0% |
| EBITDA margin | - | - | - | -16247.8% | -738.0% |
| Net margin | - | - | - | -15937.3% | -737.2% |
| Free cash flow margin | - | - | - | -14148.4% | -634.8% |
| FCF / Net income | 0.81 | 0.90 | 0.92 | 0.89 | 0.86 |
| R&D / Revenue | - | - | - | 11442.5% | 649.1% |
| SG&A / Revenue | - | - | - | 4923.9% | 134.5% |
| Effective tax rate | - | - | - | - | - |
| Return on assets | -24.2% | -115.8% | -52.1% | -41.3% | -10.2% |
| Return on equity | -25.6% | -147.5% | -59.0% | -46.0% | -10.9% |
| Return on invested capital | - | - | - | - | - |
| Liquidity | |||||
| Current ratio | 17.50 | 5.28 | 11.35 | 13.50 | 27.04 |
| Quick ratio | 17.50 | 5.28 | 11.35 | 13.50 | 27.04 |
| Cash ratio | 12.77 | 4.82 | 7.57 | 9.02 | 13.29 |
| Leverage | |||||
| Debt / Equity | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | - | - | - | - | - |
| Equity multiplier | 1.06 | 1.27 | 1.13 | 1.11 | 1.07 |
| Liabilities / Assets | 0.06 | 0.21 | 0.12 | 0.10 | 0.06 |
| Efficiency | |||||
| Asset turnover | - | - | 0.00 | 0.00 | 0.01 |
| Inventory turnover | - | - | - | - | - |
| Days sales outstanding | - | - | - | 14d | 39d |
| Days inventory outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | 7282d | 398d |
| Cash conversion cycle | - | - | - | - | - |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | 1.3x | 1.6x | 2.3x | 1.2x | 0.5x |
| P / S | - | - | - | 403.8x | 34.6x |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | - | - | -100.0% | -86.3% | - |
| Revenue CAGR (3y) | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | -84.6% | - |
| Operating income growth (YoY) | 7.3% | -9.7% | -12.9% | -202.9% | - |
| Net income growth (YoY) | 8.2% | -14.1% | -5.9% | -196.4% | - |
| EPS growth (YoY) | 37.7% | -8.5% | 1.1% | 44.8% | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | 17.4% | -11.7% | -10.0% | -205.6% | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | 427.9% | -54.3% | -17.5% | -29.6% | - |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Immuneering Corp against the 5 most active filers in the same SIC group.